HeartWare心室辅助装置在儿科患者中的血液损伤潜力
该多中心研究通过计算机模拟、体外实验和回顾性临床分析,评估HeartWare心室辅助装置(HVAD)在儿科应用中的血液损伤潜力。14例儿科患者(年龄11.3±4.8岁)的回顾性分析显示,乳酸脱氢酶和D-二聚体分别较成人HVAD患者升高1.5倍和3倍,主要出血发生率为42.9%,疑似泵血栓和神经功能障碍各占14.3%。模拟预测儿科条件下存在低于50 Pa的机械应力升高、更停滞的流场和更长冲洗时间;体外测量显示归一化溶血指数增加(17.5 vs 8.2 mg/100 L;P = .0021)。结论认为HVAD在较低转速和流量下运行会增加血液损伤。
要点
- 儿科HVAD患者乳酸脱氢酶和D-二聚体较成人分别升高1.5倍和3倍。
- 主要出血发生率为42.9%,疑似泵血栓和神经功能障碍各占14.3%。
- 体外实验显示儿科条件下归一化溶血指数显著增高(17.5 vs 8.2 mg/100 L;P = .0021)。
核心结论
- HVAD在较低转速和流量下运行会诱导更高的血液损伤。
研究设计与样本
- 多中心研究,结合计算机模拟、体外实验和14例儿科患者的回顾性临床分析。
- 儿科患者年龄11.3±4.8岁,使用HeartWare心室辅助装置。
- 体外实验使用牛血循环回路评估溶血。
主要发现
- 儿科患者乳酸脱氢酶和D-二聚体较成人HVAD患者分别升高1.5倍和3倍。
- 主要出血发生率为42.9%,疑似泵血栓和神经功能障碍各占14.3%。
- 模拟预测儿科条件下存在低于50 Pa的机械应力升高、更停滞的流场和更长冲洗时间。
- 体外测量显示归一化溶血指数增加(17.5 vs 8.2 mg/100 L;P = .0021)。
临床怎么用
- 儿科患者使用HVAD时需关注血液损伤标志物(乳酸脱氢酶、D-二聚体)及出血、血栓事件。
- 低转速和低流量运行可能增加血液损伤风险,临床需权衡利弊。
局限性
- 回顾性分析样本量小(14例),需进一步研究评估临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Mechanical circulatory support has become a standard therapy for adult patients with end-stage heart failure. For pediatric patients, technologic development lags behind with no currently approved implantable rotary blood pump. As an alternative, the HeartWare Ventricular Assist Device (Medtronic, Minneapolis, Minn), originally designed for adults, is increasingly used in pediatric patients. The aim of this multicenter study was to assess in silico, in vitro, and in vivo the blood trauma potential of this pump in pediatric application. METHODS: Clinical outcome and indicators for in vivo blood trauma were investigated retrospectively in 14 pediatric patients with the HeartWare Ventricular Assist Device (age 11.3 ± 4.8 years). Blood trauma mechanisms of the HeartWare Ventricular Assist Device were examined in silico and in vitro at an adult and pediatric operating point (5 L/min and 2.5 L/min at 2800 rpm and 2200 rpm, respectively). The flow was simulated by computational fluid dynamics and analyzed regarding flow structures, shear stresses, and washout. Hemolysis was assessed with pumps circulating bovine blood in a temperate flow circuit. RESULTS: In the retrospective in vivo analysis, lactate dehydrogenase and D-dimer values were 1.5- and 3-fold elevated, respectively, compared with adult patients with the HeartWare Ventricular Assist Device. Major bleedings were observed in 42.9%, and suspected pump thrombosis and neurologic dysfunction were observed in 14.3% of all patients. In the pediatric conditions, simulations predicted elevated mechanical stress profile below 50 Pa, more stagnant flow field, and longer washout times within the pump. In vitro measurements revealed an increased normalized index of hemolysis (17.5 vs 8.2 mg/100 L; P = .0021). CONCLUSIONS: The HeartWare Ventricular Assist Device, operated at lower speeds and flows, induces elevated blood trauma. Further studies are required to assess the clinical implications of these findings.
引用
- Granegger M, Thamsen B, Schlöglhofer T, et al. Blood trauma potential of the HeartWare Ventricular Assist Device in pediatric patients. J Thorac Cardiovasc Surg. 2019. PMID: 31444074. doi:10.1016/j.jtcvs.2019.06.084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。